Eli Lilly (LLY) Q2 2025 earnings report

Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 sales guidance to $60 billion to $62 billion, from a previous outlook of $58 billion to $61 billion on underlying strength across its business….

Read More

Novo Nordisk (NVO) earnings Q2 2025

Boxes of Ozempic and Wegovy made by Novo Nordisk at a pharmacy in London on March 8, 2024. Hollie Adams | Reuters Novo Nordisk on Wednesday posted second-quarter sales broadly in line with expectations, after last week cutting its full-year guidance and announcing its new CEO. Overall revenues rose 13% year-on-year at constant exchange rates…

Read More

Moderna (MRNA) Q2 2025 earnings

Moderna logo is seen in Warsaw, Poland on April 9, 2025. Jakub Porzycki | Nurphoto | Getty Images Moderna on Friday lowered the high end of its 2025 revenue outlook due to a delay in vaccine shipments to the U.K., but beat Wall Street’s expectations for the second quarter as it works to cut costs….

Read More

CVS Health (CVS) earnings report Q2 2025

The CVS pharmacy logo is seen outside of a storefront on August 07, 2024 in Austin, Texas.  Brandon Bell | Getty Images CVS Health on Thursday reported second-quarter earnings and revenue that topped estimates and raised its adjusted profit outlook, as it sees strength in its retail pharmacy business and some improvement in its insurance…

Read More

Merck (MRK) earnings report Q2 2025

Merck & Co. signage on the floor of the New York Stock Exchange (NYSE) in New York, US, on Tuesday, April 8, 2025. Michael Nagle | Bloomberg | Getty Images Merck on Tuesday said it will slash $3 billion in costs by the end of 2027 to be fully reinvested to support new product launches…

Read More